Trust & Proof: ULTOMIRIS (Alexion Pharmaceuticals, Inc.) – Signal Evidence & AI Readability

{
    "@context": "https://schema.org/",
    "@type": "MedicalWebPage",
    "url": "https://ultomiris.com/gmg",
    "audience": "https://health-lifesci.schema.org/Patient",
    "creator": {
        "@type": "Organization",
        "name": "Alexion Pharmaceuticals, Inc.",
        "url": "https://alexion.com",
        "logo": "https://alexion.com/~/media/Alexion_comRedesign/Images/Logos/alexion.svg",
        "sameAs": "https://en.wikipedia.org/wiki/Alexion_Pharmaceuticals"
    },
    "specialty": [
        "https://health-lifesci.schema.org/Neurologic",
        "https://health-lifesci.schema.org/Musculoskeletal"
    ],
    "mainEntity": {
        "@type": "Drug",
        "name": "ULTOMIRIS",
        "brand": {
            "@type": "Brand",
            "name": "ULTOMIRIS",
            "logo": "https://ultomiris.com/gmg/-/media/ultomiris_gmg/images/logo/ultomiris-logo.svg",
            "sameAs": "https://en.wikipedia.org/wiki/Ravulizumab"
        },
        "activeIngredient": "ravulizumab-cwvz",
        "administrationRoute": "IV infusion",
        "isProprietary": "True",
        "isAvailableGenerically": "False",
        "nonProprietaryName": "",
        "relevantSpecialty": "https://health-lifesci.schema.org/Neurologic",
        "manufacturer": {
            "@type": "Organization",
            "name": "Alexion Pharmaceuticals, Inc.",
            "url": "https://alexion.com",
            "logo": "https://alexion.com/~/media/Alexion_comRedesign/Images/Logos/alexion.svg",
            "sameAs": "https://en.wikipedia.org/wiki/Alexion_Pharmaceuticals"
        },
        "description": "Learn about ULTOMIRIS, a treatment for generalized myasthenia gravis (gMG). Please see the accompanying full Prescribing Info and Med Guide, including Boxed WARNING.",
        "dosageForm": "Injection",
        "drugUnit": "10 mg/mL, 100 mg/mL in a single-dose vial",
        "interactingDrug": {
            "@type": "Drug",
            "name": ""
        },
        "doseSchedule": [
            {
                "@type": "DoseSchedule",
                "doseUnit": "mg/mL",
                "doseValue": "300 mg/30 mL",
                "frequency": "Once every 8 weeks after an initial loading dose",
                "targetPopulation": "Adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive"
            },
            {
                "@type": "DoseSchedule",
                "doseUnit": "mg/mL",
                "doseValue": "300 mg/3 mL, 1,100 mg/11 mL",
                "frequency": "Once every 8 weeks after an initial loading dose",
                "targetPopulation": "Adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive"
            },
            {
                "@type": "DoseSchedule",
                "doseUnit": "mg/mL",
                "doseValue": "1,100 mg/11 mL",
                "frequency": "Once every 8 weeks after an initial loading dose",
                "targetPopulation": "Adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive"
            }
        ],
        "labelDetails": [
            "https://alexion.com/Documents/Ultomiris_USPI.pdf",
            "ttps://ultomiris.com/Pdf/ULTOMIRIS-Med-Guide.pdf"
        ],
        "mechanismOfAction": "ULTOMIRIS is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the membrane attack complex [MAC or C5b-9]), thus preventing MAC formation. The precise mechanism by which ravulizumab-cwvz exerts its therapeutic effect in gMG patients is unknown, but is presumed to involve reduction of terminal complement complex C5b-9 deposition at the neuromuscular junction.",
        "prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
        "prescribingInfo": "https://alexion.com/Documents/Ultomiris_USPI.pdf",
        "breastfeedingWarning": "Before you receive ULTOMIRIS, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS will harm your unborn baby or if it passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS.",
        "pregnancyWarning": "Before you receive ULTOMIRIS, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS will harm your unborn baby or if it passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS."
    },
    "about": {
        "@type": "MedicalCondition",
        "name": "generalized myasthenia gravis",
        "sameAs": "https://en.wikipedia.org/wiki/Ravulizumab",
        "relevantSpecialty": [
            "https://health-lifesci.schema.org/Neurologic",
            "https://health-lifesci.schema.org/Musculoskeletal"
        ],
        "alternateName": "gMG",
        "associatedAnatomy": {
            "@type": "AnatomicalSystem",
            "name": "Central nervous system "
        },
        "possibleTreatment": {
            "@type": "MedicalTherapy",
            "name": "ULTOMIRIS"
        }
    }
}